Congenital hypogonadotropic hypogonadism (CHH) is characterized by lack of normal pubertal development due to deficient gonadotropin-releasing hormone (GnRH) secretion or action, and is caused by genetic defects in several genes. Mutations in the CHD7 gene cause CHARGe syndrome (Coloboma of the eye, Heart defects, Atresia of the choanae, Retardation of growth and development, Genital hypoplasia and ear abnormalities), but have also been found in patients with isolated CHH. the aim of this study was to identify CHD7 mutations in patients with CHH. Fifty portuguese patients with CHH were screened for mutations in the CHD7 gene by DNA sequencing. Eight (16%) patients had CHD7 rare sequence variants that consisted of six missense (p .Gly388Glu, p.His903Pro, p.Thr1082Ile,  p.Val1452Leu, p.Asp1854Gly, and p.Arg2065His) and two synonymous (p.Ser559Ser, and p.Ala2785Ala) mutations. Five of these mutations have never been reported before. three CHD7 mutations occurred in patients that had mutations in additional CHH-genes. this study uncovered novel genetic variants that expand the known spectrum of mutations associated with CHH. the frequency of CHD7 mutations in this cohort was higher than that of other major CHH-genes and confirms the importance of including CHD7 in the genetic testing of CHH, even in the absence of additional CHARGe features.
Genetic studies. Genomic deoxyribonucleic acid (DNA) was extracted from peripheral blood leucocytes using previously described methods 13 . Patients had already been screened for mutations in the ANOS1, FGFR1 and GNRHR genes, resulting in the discovery of three mutations in ANOS1 14 , six mutations in FGFR1 15 and six mutations in GNRHR 16 . All 50 patients were subsequently screened for mutations in the CHD7 gene by polymerase chain reaction (PCR) amplification of the coding exons and exon-intron boundaries, and bi-directional sequencing using CEQ DTCS sequencing kit (Beckman Coulter, Fullerton, CA, USA) and an automated capillary DNA sequencer (GenomeLab TM GeXP, Genetic Analysis System, Beckman Coulter). Primer sequences for CHD7 were previously described by Song et al. 17 , except for the primer sequence of exons 2.4 and 3, which were designed using Primer 3 Plus 18 . Genomic sequence variants identified in patients were searched in the Exome Aggregation Consortium (ExAC) population variant database 19 , to assess their frequency in the general population. Variants found to be absent in the ExAC database or with frequencies <0.1% were further screened in a panel of at least 200 healthy Portuguese volunteers (400 alleles), using allele-specific PCR or sequence-specific restriction enzymes, to exclude the possibility that they represented common polymorphisms in the Portuguese population. Variants were considered to be pathogenic when they were simultaneously found to have an ExAC population frequency <0.1%, to be absent in the Portuguese control population, and to have a deleterious effect predicted by at least one of four bioinformatic programs (SIFT 20 , PolyPhen-2 21 , Mutation Taster 22 or Human Splicing Finder 23 ). Sequence variant nomenclature followed standard guidelines 24 and was based on the cDNA reference sequence for the CHD7 gene (GenBank accession NM_017780.3). Patients with pathogenic variants in CHD7 were further screened for mutations in additional genes related to the hypothalamic-pituitary-gonadal axis (PROKR2, PROK2, FGF8, GNRH1, KISS1R, TAC3 and TACR3), to identify possible cases of oligogenicity (primer sequences and PCR conditions are available upon request).
Results
Sequence analysis of the entire coding region and exon-intron boundaries of CHD7 revealed 13 heterozygous variants that had frequencies <0.1% in the ExAC population database. Five of these variants were detected in normal Portuguese controls (p.Thr689Thr, 2 of 408 alleles; p.Lys729Glu, 1 of 436 alleles; c.2613 + 4 C > T, 1 of 454 alleles; p.Gly1479Gly, 1 of 398 alleles; p.Pro2072Pro, 1 of 450 alleles) and were excluded from further analysis. The remaining eight variants were found to be absent in the Portuguese control population and were predicted to cause changes in protein function, by at least one bioinformatic prediction program ( . 1 ). Conservation analysis revealed that, with the exception of p.Gly388Glu, all missense variants occurred at amino acids that were highly conserved across species (Supplemental Table 1 ). The p.Ser559Ser, p.Arg2065His and p.Ala2785Ala variants, have been previously identified in patients with CHARGE syndrome 25 . The remaining five variants have not yet been reported in patients with either CHH or CHARGE syndrome.
In six of the eight families, it was possible to determine the parental origin of the CHD7 mutation and in all six cases the mutation was transmitted by a parent who did not have CHARGE symptoms or a history of delayed puberty ( Fig. 1 ). In three of these cases, patients presented mutations in additional CHH genes, namely one digenic mutation (CHD7/FGFR1) and two trigenic mutations (CHD7/FGFR1/PROKR2), thus representing cases of oligogenic inheritance (Fig. 1) .
All CHD7 variants were submitted to the CHD7 mutation database at www.chd7.org. The clinical characteristics of patients with identified CHD7 pathogenic variants are summarized in Table 2 .
Discussion
The overall prevalence of CHD7 mutations in this cohort of Portuguese patients with CHH was 16% (8 out of 50), with a similar distribution between the KS and nCHH forms. This is a high prevalence when compared to the contribution of other genes that have been historically considered as priorities in the genetic study of CHH, namely the ANOS1 (KAL1), FGFR1, and GNRHR genes 26 . Indeed, previous studies in the Portuguese population have shown that the ANOS1 (KAL1), FGFR1, and GNRHR genes are mutated in only 7.1%, 12.0%, and 12.5% of cases, respectively [14] [15] [16] . Studies in other populations have also shown an important contribution of CHD7 mutations in the aetiology of CHH, with frequencies ranging from 5.2% to 19.0%, of cases [6] [7] [8] [9] [10] [11] . Thus, the CHD7 gene is becoming increasingly recognised as one of the most commonly mutated genes in CHH. Although CHD7 mutations can cause both CHARGE syndrome and isolated CHH, it is likely that this variable phenotypic expression is related to the severity of the CHD7 mutations, as mutations in CHARGE syndrome are typically highly deleterious protein-truncating mutations, whereas CHD7 mutations in isolated CHH are typically missense 8 . Accordingly, in our CHH patients, all identified CHD7 mutations were either missense (n = 6) or synonymous (n = 2).
The eight CHD7 mutations identified in this study were found to be absent or very rare (<0.1%) in the ExAC population database 19 , absent in Portuguese controls, and predicted to be damaging by structure-and sequence-based bioinformatics programs [20] [21] [22] [23] . Three of these mutations (one missense and two synonymous) have already been reported in patients with CHARGE syndrome 25 , and the remaining five missense mutations have not yet been reported in patients with either CHH or CHARGE syndrome. The missense mutations occurred at highly conserved amino acids. Furthermore, the p.His903Pro, p.Thr1082Ile and p.Val1452Leu mutations are located in chromodomain 2, the SNF2 domain and the helicase domain, respectively, which play important roles in the chromatin remodelling activity of the CHD7 protein 6 . The remaining missense mutations occurred outside these catalytic domains but were also predicted to affect protein function. The mechanisms by which the synonymous mutations exert their effect were not possible to determine. However, synonymous mutations -sometimes called 'silent' mutations -are widely acknowledged to be able to cause changes in protein expression, conformation and function, and have been implicated in several diseases 27 . It should be noted however that according to more stringent classification criteria recommended by the American College of Medical Genetics and Genomics (ACMG) 28 , only the p.Thr1082Ile variant is considered "likely pathogenic" and the remaining are considered "variants of uncertain significance". Three patients with CHD7 mutations presented additional defects in known CHH-genes. Thus, these represent cases of oligogenic inheritance, which is a frequent genetic finding in CHH 29 . Oligogenicity might explain some cases of incomplete penetrance, where carriers of a CHD7 mutation only express CHH in the presence of other mutated genes.
Our patients with CHD7 mutations did not undergo detailed radiological investigations to detect hypoplasia/ agenesis of semicircular canals or of olfactory bulbs and tracts, which are currently major criteria for CHARGE syndrome 30, 31 . Thus, we cannot exclude that patients have light forms of CHARGE syndrome. Other studies have shown that a subset of patients with apparently isolated CHH, in whom a CHD7 defect was demonstrated, were subsequently found to exhibit multiple CHARGE features and reclassified as having CHARGE syndrome [32] [33] [34] . Interestingly, three of our patients with CHD7 mutations had minor CHARGE features 30, 31 , namely hearing deficit, renal anomalies and intellectual disability, respectively, but insufficient for a clinical diagnosis of CHARGE syndrome. It remains to be determined if these were coincidental findings or the result of the CHD7 mutations.
Our results should be viewed with caution as in vitro and in vivo functional tests are not readily available for CHD7 35 , and therefore it was not possible to confirm the damaging effect of the observed CHD7 variants. In addition, a limited number of CHH-genes was analysed by Sanger sequencing and it remains to be determined if a more comprehensive genetic analysis (e.g. through whole exome sequencing) would uncover additional cases of oligogenicity and explain the incomplete penetrance observed in some families. Finally, CHH is clinically heterogeneous and sometimes overlaps with constitutional delay of growth and puberty (CDGP) 36 . Our study included patients with a wide range of ages and we cannot exclude the possibility that some of the younger patients, who underwent medically induced puberty, may represent cases of CDGP or mild forms of CHH that would have eventually developed spontaneous late puberty. Therefore, our results may not be directly comparable with those of other studies that used different inclusion criteria.
In conclusion, our study identified a high frequency of CHD7 mutations in patients with CHH and uncovered novel genetic variants that expand the known spectrum of mutations associated with CHH.
